Literature DB >> 22094583

Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation.

D Xu, J Hu, S Xu, E De Bruyne, E Menu, B Van Camp, K Vanderkerken, E Van Valckenborgh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22094583     DOI： 10.1038/leu.2011.332

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  21 in total

Review 1.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

Review 2.  Modulatory effects of bortezomib on host immune cell functions.

Authors:  Samuel Troy Pellom; Duafalia Fred Dudimah; Menaka Chanu Thounaojam; Thomas Joseph Sayers; Anil Shanker
Journal:  Immunotherapy       Date:  2015-09-01       Impact factor: 4.196

3.  Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.

Authors:  Jesus Delgado-Calle; Judith Anderson; Meloney D Cregor; Masahiro Hiasa; John M Chirgwin; Nadia Carlesso; Toshiyuki Yoneda; Khalid S Mohammad; Lilian I Plotkin; G David Roodman; Teresita Bellido
Journal:  Cancer Res       Date:  2016-02-01       Impact factor: 12.701

4.  In Situ OH Generation from O2- and H2O2 Plays a Critical Role in Plasma-Induced Cell Death.

Authors:  Dehui Xu; Dingxing Liu; Biqing Wang; Chen Chen; Zeyu Chen; Dong Li; Yanjie Yang; Hailan Chen; Michael G Kong
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 5.  Fact or fiction--identifying the elusive multiple myeloma stem cell.

Authors:  Joshua Kellner; Bei Liu; Yubin Kang; Zihai Li
Journal:  J Hematol Oncol       Date:  2013-12-07       Impact factor: 17.388

6.  Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.

Authors:  R Schwarzer; N Nickel; J Godau; B M Willie; G N Duda; R Schwarzer; B Cirovic; A Leutz; R Manz; B Bogen; B Dörken; F Jundt
Journal:  Blood Cancer J       Date:  2014-06-13       Impact factor: 11.037

7.  Notch signaling drives multiple myeloma induced osteoclastogenesis.

Authors:  Michela Colombo; Katja Thümmler; Leonardo Mirandola; Silvia Garavelli; Katia Todoerti; Luana Apicella; Elisa Lazzari; Marialuigia Lancellotti; Natalia Platonova; Moeed Akbar; Maurizio Chiriva-Internati; Richard Soutar; Antonino Neri; Carl S Goodyear; Raffaella Chiaramonte
Journal:  Oncotarget       Date:  2014-11-15

8.  Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity.

Authors:  Hayley M Sabol; Adam J Ferrari; Manish Adhikari; Tânia Amorim; Kevin McAndrews; Judith Anderson; Michele Vigolo; Rajwinder Lehal; Meloney Cregor; Sharmin Khan; Pedro L Cuevas; Jill A Helms; Noriyoshi Kurihara; Venkat Srinivasan; Frank H Ebetino; Robert K Boeckman; G David Roodman; Teresita Bellido; Jesus Delgado-Calle
Journal:  Cancer Res       Date:  2021-08-04       Impact factor: 12.701

Review 9.  Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.

Authors:  Jahangir Abdi; Guoan Chen; Hong Chang
Journal:  Oncotarget       Date:  2013-12

Review 10.  Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  J A McCubrey; L S Steelman; F E Bertrand; N M Davis; S L Abrams; G Montalto; A B D'Assoro; M Libra; F Nicoletti; R Maestro; J Basecke; L Cocco; M Cervello; A M Martelli
Journal:  Leukemia       Date:  2013-06-19       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.